LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Total Current Liabilities

Last Annual Value

7.44M

3-Year CAGR

151%

5-Year CAGR

74%

10-Year CAGR

32%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Total Current Liabilities

LBRX · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
7.44M
41.9%N/AN/A 
18.38M
14.2%20.1%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
42.63M
33.5%14.4%N/A
46.25M
-9.9%-0.3%3.4%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
18.37M
-0.1%10.7%N/A
36.49M
22.5%18.0%N/A
49.41M
12.7%1.1%N/A
62.36M
22.6%33.8%N/A
15.44M
-12.1%-6.6%N/A
30.21M
-14.6%6.4%15.4%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
11.94M
-15.1%0.9%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95